Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy

Clinical Infectious Diseases

Volumn 50, Issue 5, 2010, Pages 773-778

  Canestri, Ana ^a,e   Lescure, François Xavier ^a   Jaureguiberry, Stephane ^a   Moulignier, Antoine ^a   Amiel, Corinne ^b   Marcelin, Anne Geneviève ^a,d,e   Peytavin, Gilles ^c   Tubiana, Roland ^a,e   Pialoux, Gilles ^a,d   Katlama, Christine ^a,d,e  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL TENON   (France)

^c BICHAT HOSPITAL   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NEUROLOGIC DISEASE; PLASMA; PLEOCYTOSIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; VIREMIA; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ADULT; AGED; AIDS-ASSOCIATED NEPHROPATHY; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CEREBROSPINAL FLUID; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PLASMA; RNA, VIRAL; VIRAL LOAD;

EID: 76749136667     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/650538     Document Type: Article

References (29)

1. Gorry PR, Bristol G, Zack JA, et al. Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol 2001;75(21): 10073-10089. (Pubitemid 32948038)
2. Peters PJ, Bhattacharya J, Hibbitts S, et al. Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages. J Virol 2004; 78(13):6915-6926. (Pubitemid 38781530)
3. Tambussi G, Gori A, Capiluppi B, et al. Neurological symptoms during primary human immunodeficiency virus (HIV) infection correlate with high levels of HIV RNA in cerebrospinal fluid. Clin Infect Dis 2000; 30(6):962-965. (Pubitemid 32250348)
4. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007;69(18):1789-1799.
5. Ellis RJ, Moore DJ, Childers ME, et al. Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol 2002; 59(6) :923-928.
6. Polis MA, Suzman DL, Yoder CP, et al. Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen. AIDS 2003;17(8):1167-1172.
7. Mellgren A, Antinori A, Cinque P, et al. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antivir Ther 2005;10(6);701-707. (Pubitemid 41376848)
8. Eggers C, Hertogs K, Sturenburg HJ, van Lunzen J, Stellbrink HJ. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS 2003;17(13):1897-1906. (Pubitemid 37070275)
9. Marra CM, Lockhart D, Zunt JR, Perrin M, Coombs RW, Collier AC. Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology 2003;60(8):1388-1390. (Pubitemid 36461005)
10. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009;23(11):1359-1366.
11. Ferrando SJ, Rabkin JG, van Gorp W, Lin SH, McElhiney M. Longitudinal improvement in psychomotor processing speed is associated with potent combination antiretroviral therapy in HIV-1 infection. J Neuropsychiatry Clin Neurosci 2003; 15(2);208-214. (Pubitemid 36520341)
12. Cysique LA, Vaida F, Letendre S, et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 2009; 73:342-348.
13. Robertson KR, Robertson WT, Ford S, et al. Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr 2004;36:562-566. (Pubitemid 38544504)
14. d'Arminio Monforte A, Cinque P, Mocroft A, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004; 55(3):320-328.
15. Nath A, Berger J. HIV Dementia. Curr Treat Options Neurol 2004; 6(2):139-151.
16. Robertson KR, Smurzynski M., Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007; 21(14):1915-1921. (Pubitemid 47329768)
17. Spudich S, Lollo N, Liegler T, Deeks SG, Price RW Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis 2006; 194(12):1686-1696. (Pubitemid 44901999)
18. Letendre S. MD, Ellis R. et al. Persistent HIV in the central nervous system during treatment is associated with worse ART penetration and cognitive impairment. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections (Montreal). 8-11 February 2009. Abstract 484b.
19. Wendel KA, McArthur JC. Acute meningoencephalitis in chronic human immunodeficiency virus (HIV) infection: putative central nervous system escape of HIV replication. Clin Infect Dis 2003;37(8):1107-1111.
20. Ghosn J, Wirden M, Ktorza N, et al. No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients. AIDS 2005;19(15):1643-1647. (Pubitemid 41502677)
21. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65(1):65-70.
22. Offiah CE, Turnbull IW The imaging appearances of intracranial CNS infections in adult HIV and AIDS patients. Clin Radiol 2006;61(5): 393-401.
23. Villar Del Saz S, Sued O, Falco V, et al. Acute meningoencephalitis due to human immunodeficiency virus type 1 infection in 13 patients: clinical description and follow-up. J Neurovirol 2008 Nov 26:1-6 (Epub ahead of print).
24. Langford D, Marquie-Beck J, de Almeida S, et al. Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. J Neurovirol 2006; 12(2): 100-107. (Pubitemid 44574601)
25. Smit TK, Brew BJ, Tourtellotte W, Morgello S, Gelman BB, Saksena NK. Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J Virol 2004; 78(18): 10133-10148. (Pubitemid 39187131)
26. Harrington PR, Haas DW, Ritola K, Swanstrom R. Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells. J Virol 2005;79(13):7959-7966. (Pubitemid 40853500)
27. Cunningham PH, Smith DG, Satchell C, Cooper DA, Brew B. Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS 2000; 14(13): 1949-1954. (Pubitemid 30688589)
28. Schnell G, Spudich S, Harrington P, Price RW, Swanstrom R. Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog 2009;5(4):e1000395.
29. Gutmann C, Opravil M, Fux C, et al. Unexpectedly high failure rate in LPV/r monotherapy arm, involving CNS, and association with low nadir CD4 count in the MOST study. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections (Montréal). 2009. Abstract 189.